Updates on immunotherapy for colorectal cancer

被引：126
作者：
Kalyan, Aparna [1 ,2 ]
Kircher, Sheetal [2 ]
Shah, Hiral [1 ,2 ]
Mulcahy, Mary [2 ]
Benson, Al [2 ]
机构：
[1] Feinberg Sch Med, Div Hematol & Oncol, Dev Therapeut Program, Chicago, IL USA
[2] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA
来源：
JOURNAL OF GASTROINTESTINAL ONCOLOGY | 2018年 / 9卷 / 01期
关键词：
Colorectal cancer (CRC); immunotherapy; microsatellite instability (MSI); vaccine therapy; ACTIVE SPECIFIC IMMUNOTHERAPY; PHASE-I; COLON-CANCER; CARCINOEMBRYONIC ANTIGEN; LIVER METASTASES; DENDRITIC CELLS; TUMOR-CELLS; PEPTIDE; VACCINE; VIRUS;
D O I：
10.21037/jgo.2018.01.17
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Despite significant advances in standard of care therapies, the 5-year survival rate for metastatic colorectal cancer (CRC) remains around 12%. Immunotherapy has not provided the stellar advances in colorectal cancer that has been seen in other malignancies. Immunotherapy appears to play a pivotal role in microsatellite unstable CRC tumors where the response rates are profound. These results have led to FDA approval of pembrolizumab for MSI-H CRC tumors. Additional research into several new immune agents including IDO inhibitors, vaccine therapy and combinatorial agents are being evaluated for CRC. This review will provide an overview of the approaches currently being investigated.
引用
收藏
页码：160 / 169
页数：10
相关论文
共 78 条
[1]   Efficacy of an EGFR-Specific Peptide against EGFR-Dependent Cancer Cell Lines and Tumor Xenografts [J].
Ahsan, Aarif ;
Ramanand, Susmita G. ;
Bergin, Ingrid L. ;
Zhao, Lilli ;
Whitehead, Christopher E. ;
Rehemtulla, Alnawaz ;
Ray, Dipankar ;
Pratt, William B. ;
Lawrence, Theodore S. ;
Nyati, Mukesh K. .
NEOPLASIA, 2014, 16 (02) :105-+
[2]  
[Anonymous], J CLIN ONCOL
[3]  
[Anonymous], ONCOIMMUNOL
[4]   Global patterns and trends in colorectal cancer incidence and mortality [J].
Arnold, Melina ;
Sierra, Monica S. ;
Laversanne, Mathieu ;
Soerjomataram, Isabelle ;
Jemal, Ahmedin ;
Bray, Freddie .
GUT, 2017, 66 (04) :683-691
[5]   Rationale for anti-OX40 cancer immunotherapy [J].
Aspeslagh, Sandrine ;
Postel-Vinay, Sophie ;
Rusakiewicz, Sylvie ;
Soria, Jean-Charles ;
Zitvogel, Laurence ;
Marabelle, Aurelien .
EUROPEAN JOURNAL OF CANCER, 2016, 52 :50-66
[6]   Carcinoembryonic antigen as a target for therapeutic anticancer vaccines: A review [J].
Berinstein, NL .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (08) :2197-2207
[7]   Phase I Study of Single-Agent Anti-Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates [J].
Brahmer, Julie R. ;
Drake, Charles G. ;
Wollner, Ira ;
Powderly, John D. ;
Picus, Joel ;
Sharfman, William H. ;
Stankevich, Elizabeth ;
Pons, Alice ;
Salay, Theresa M. ;
McMiller, Tracee L. ;
Gilson, Marta M. ;
Wang, Changyu ;
Selby, Mark ;
Taube, Janis M. ;
Anders, Robert ;
Chen, Lieping ;
Korman, Alan J. ;
Pardoll, Drew M. ;
Lowy, Israel ;
Topalian, Suzanne L. .
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (19) :3167-3175
[8]   Prognostic value of indoleamine 2,3-dioxygenase expression in colorectal cancer:: Effect on tumor-infiltrating T cells [J].
Brandacher, G ;
Perathoner, A ;
Ladurner, R ;
Schneeberger, S ;
Obrist, P ;
Winkler, C ;
Werner, ER ;
Werner-Felmayer, G ;
Weiss, HG ;
Göbel, G ;
Margreiter, R ;
Königsrainer, A ;
Fuchs, D ;
Amberger, A .
CLINICAL CANCER RESEARCH, 2006, 12 (04) :1144-1151
[9]   OX40 engagement depletes intratumoral Tregs via activating FcγRs, leading to antitumor efficacy [J].
Bulliard, Yannick ;
Jolicoeur, Rose ;
Zhang, Jimin ;
Dranoff, Glenn ;
Wilson, Nicholas S. ;
Brogdon, Jennifer L. .
IMMUNOLOGY AND CELL BIOLOGY, 2014, 92 (06) :475-480
[10]   Intratumor OX40 stimulation inhibits IRF1 expression and IL-10 production by Treg cells while enhancing CD40L expression by effector memory T cells [J].
Burocchi, Alessia ;
Pittoni, Paola ;
Gorzanelli, Andrea ;
Colombo, Mario P. ;
Piconese, Silvia .
EUROPEAN JOURNAL OF IMMUNOLOGY, 2011, 41 (12) :3615-3626
12345678